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Abstract
Background: Gender differences in organ involvement and clinical severity have been poorly described in
hereditary hemorrhagic telangiectasia (HHT). The aim of this study was to describe differences in the severity of
HHT manifestations according to gender.
Methods: Severity was measured according to Epistaxis Severity Score (ESS), Simple Clinical Scoring Index for
hepatic involvement, a general HHT-score, needing for invasive treatment (pulmonary or brain arteriovenous
malformations -AVMs- embolization, liver transplantation or Young’s surgery) or the presence of adverse outcomes
(severe anemia, emergency department -ED- or hospital admissions and mortality).
Results: One hundred forty-two (58.7%) women and 100 (41.3%) men were included with a mean age of 48.9 ±
16.6 and 49 ± 16.5 years, respectively. Women presented hepatic manifestations (7.1% vs 0%) and hepatic
involvement (59.8% vs 47%), hepatic AVMs (28.2% vs 13%) and bile duct dilatation (4.9% vs 0%) at abdominal CT,
and pulmonary AVMs at thoracic CT (35.2% vs 23%) more often than men. The Simple Clinical Scoring Index was
higher in women (3.38 ± 1.2 vs 2.03 ± 1.2), and more men were considered at low risk of harboring clinically
significant liver disease than women (61% vs 25.3%). These differences were mantained when considering HHT1
and HHT2 patients separetely. Duodenal telangiectasia were more frequent in men than women (21% vs 9.8%).
Invasive treatments were more frequently needed in women (28.2% vs 16%) but men needed attention at the ED
more often than women (48% vs 28.2%), with no differences in ESS, HHT-score, anemia hospital admissions or
mortality.
Conclusions: HHT women showed more severe hepatic involvement than men, also among HHT1 and HHT2
patients. Women had higher prevalence of pulmonary AVMs and needed invasive procedures more frequently,
while men needed attention at the ED more often. These data might help physicians to individualize HHT patients
follow-up.
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Introduction
Hereditary hemorrhagic telangiectasia (HHT) or Rendu-
Osler-Weber syndrome (ORPHA774) is a rare autosomal-
dominant vascular disease characterized by telangiectases
and larger vascular malformations (VMs) [1, 2]. Mutations
in endoglin (ENG) and activin A receptor type II-like 1
(ACVRL1) genes are detected in approximately 90% of
cases submitted to molecular diagnosis for clinical suspi-
cion of HHT and cause HHT1 or HHT2, respectively [3–
6]. Mutations in SMAD4 (encoding the transcription fac-
tor Smad4) have been described in less than 2% of the
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HHT population and cause juvenile polyposis/HHT over-
lap syndrome [3]. Endoglin (encoded by ENG) is an auxil-
iary co-receptor at the endothelial cell surface that
promotes BMP9 signalling through the activin receptor-
like kinase 1 (ALK1; encoded by ACVRL1). Both proteins
contribute to the signalling hub formed by BMP9-
Endoglin-ALK1-Smad with high impact in angiogenesis
[7].
HHT can be diagnosed either through molecular gen-
etic test or using the Curaçao clinical criteria (recurrent
epistaxis, muco-cutaneous telangiectasia, visceral lesions
and family history) [8–10]. Telangiectasia is the hallmark
in HHT and shows dilated post capillary venules directly
connected with dilated arterioles losing the capillary bed
[11]. Telangiectasia in nasal mucosae cause spontaneous
and recurrent epistaxis which is the most common and
usually the earliest clinical manifestation of HHT [4, 6,
12, 13]. Pulmonary arteriovenous malformations (AVMs)
and brain VMs are more common in patients with
HHT1 and vascular hepatic malformations in HHT2 pa-
tients [4, 8, 14–17]. Despite these phenotype patterns,
there is significant intra-familial as well as inter-familial
clinical variability among HHT patients [18]. Screening
for possible VMs is recommended for early detection
and appropiate treatment [10, 19, 20].
Although the offspring of HHT patients have a 50%
chance of inheriting a mutation, some studies have
found a higher prevalence of HHT in women compared
with men [12, 21, 22]. One possible explanation for this
observation is that women have significantly higher rates
of consultation with primary care providers, but the ex-
istence of other biological reasons is unknown [23].
Moreover, the evidence of gender influence in HHT se-
verity is scarce and not directly addressed [10, 12, 24,
25]. Data from the largest series of HHT patients with
liver transplantation from the European Liver Transplant
Registry, showed that 35 (87.5%) out of 40 patients were
women [24]. Actually, female gender was considered as
a risk factor in a multivariate analysis when defining a
score for clinically significant hepatic involvement in
HHT [19]. Nonetheless, gender was not found to be as-
sociated with adverse outcomes in a series of 393 pa-
tients that defined a severity score for HHT [25].
However, most of these studies focused on isolated
organ involvement and were not specifically designed to
analyze gender differences. In the present study, we




This is a prospective non-interventional study including
all consecutive patients visited in a HHT multidisciplin-
ary referral unit in a university hospital. This HHT Unit
serves adult patients from all over Catalonia (Spain),
which is about 7.5 million inhabitants. The study period
was September 2011 to January 2019. Patients with a
“definite” diagnosis according to the Curaçao Criteria
(meet ≥3 criteria) or a positive genetic study, were in-
cluded. Patients who met < 3 Curaçao Criteria without
positive genetic test, and those in whom screening was
not completed, were excluded [8–10]. Oral informed
consent was obtained from all participants. The study
was approved by the Clinical Research Ethics Committee
of the Hospital Universitari de Bellvitge. We followed
the Strengthening the Reporting of Observational Stud-
ies in Epidemiology (STROBE) statement guidelines for
observational cohort studies [26].
The aim of the study was to assess differences in clin-
ical severity according to gender in a large series of pa-
tients with objectively confirmed HHT. A secondary
objective was to analyze gender differences in severity
among patients with HHT1 or HHT2, separately.
Screening for vascular involvement
Clinical characteristics at baseline and complementary
tests were prospectively collected. Screening for vascular
involvement was done according to guidelines and ex-
pert’s recommendations [9, 10, 27]. All patients were ex-
amined by an ear, nose and throat (ENT) physician
expert on HHT. Anemia was defined as hemoglobin
levels < 12 g/dL in women and < 13 g/dL in men. Iron
deficiency was defined as blood ferritin levels < 15 μg/L.
Hepatic manifestations were defined as clinical ische-
mic cholangitis or right-upper abdominal pain with bile
duct dilation, signs and symptoms of high-output car-
diac failure secondary to hepatic involvement, or hepatic
encephalopathy in patients with objectively confirmed
hepatic VMs [10, 28]. Pulmonary manifestations in pa-
tients with pulmonary AVMs were defined as the pres-
ence of respiratory failure (PaO2 < 60mmHg) without
any other etiologic cause, hemoptysis, stroke or transient
ischemic attack without cardiac arrhythmia or associated
myocardiopathy, or brain abscess.
In order to calculate cardiac index (L/min/m2) and for
the screening of pulmonary visceral involvement, a con-
trast transthoracic echocardiography (TTE) was per-
formed [10, 27]. The Barzilai scale was used to establish
the degree of right-left (R-L) shunt [29]. All patients with
R-L shunt Grade ≥ 2 and those with previous pulmonary
AVMs embolitzation underwent a thoracic computed
tomography (CT) to objectively confirm the presence of
pulmonary AVMs. In addition, an abdominal CT was per-
formed to study hepatic and/or other abdominal AVMs.
Hepatic involvement at CT was defined according to the
presence of telangiectasia, tortuous or enlarged hepatic ar-
tery (> 6mm diameter), any of the three classical patterns
of HHT vascular shunts (portovenous, arteriovenous or
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arterioportal) or regenerative or nodal focular hyperplasia
[10, 28]. Other intraabdominal vascular involvement ra-
ther than hepatic, were also recorded.
Neurological involvement studies were carried out in
cases of neurological symptoms or family history by a
cerebral CT and/or magnetic resonance imaging (MRI)
[10]. A gastrointestinal (GI) endoscopic digestive study
was performed when there was disproportionate anemia
to the degree of epistaxis or objectively confirmed overt
GI bleeding [10, 27].
HHT severity assessment
A clinical follow-up was carried out according to each of
patient’s needs. HHT clinical severity was assessed using
the following five items: Epistaxis Severity Score (ESS),
Simple Clinical Scoring Index for clinically significant
hepatic involvement, HHT-score, the need for invasive
treatment or the presence of adverse outcomes related
to HHT [19, 25, 30].
The ESS is an on-line tool that quantifies the severity
of epistaxis according to different parameters occurring
within the previous three months [30]. The ESS ranges
from 0 to 10, defining epistaxis as mild (ESS 1–4), mod-
erate (ESS 4–7) or severe (ESS ≥7). For each patient,
baseline ESS and mean ESS assessed at each visit during
follow-up were registered.
Liver involvement severity was determined by the Sim-
ple Clinical Scoring Index [19]. This index include four
simple variables: age, gender, hemoglobin and serum al-
kaline phosphatase. The score ranges from 0 to 9 and
stratifies patients with a value score < 3 to be at low-risk
(< 5% probability), 3–5 at intermediate risk (5–80%
probability) and ≥ 6 at high-risk (> 80% probability) of
harboring clinically significant liver disease.
The HHT-score was calculated based on: chronic
bleeding (maximum 2 points), presence of AVMs (max-
imum 3 points) and severe organ involvement (max-
imum 2 points) [25]. Patients were categorized as having
mild (0–2), moderate (3–4) or severe (5–7) HHT
disease.
Specific invasive treatment strategies were defined as
pulmonary or brain VM’s embolization, liver transplant-
ation or Young’s surgery [31]. Emergency Department
(ED) assistance, hospital admission, severe anemia and
overall mortality during follow-up were considered as
adverse outcomes. Severe anemia was defined as
hemoglobin level < 8 g/dL or the need for red blood cell
(RBC) transfusion.
Statistical analysis
A descriptive statistical analysis was performed for all
categorical and continuous variables and expressed as
proportions or means with standard deviations (SD), re-
spectively. We used chi-square or Fisher’s exact tests to
compare categorical data between groups. Continuous
variables were compared using Student t test. Hazard ra-
tios (HR) and corresponding 95% confidence intervals
(CI) were calculated. We used two-tailed unpaired t-
tests to compare normally distributed continuous data
between two groups, and we used the Mann-Whitney U
test for non-normally distributed continuous data com-
parisons. P values of < 0.05 were considered statistically
significant. Analyses were performed using SPSS, version
18 for the PC (SPSS, Inc. Chicago, IL, USA).
Results
Baseline characteristics
During the study period, 290 patients attended our HHT
multidisciplinary referral unit. Among them, 48 (16.5%)
patients were excluded, 26 patients met < 3 Curaçao Cri-
teria without a positive genetic test and 22 because
screening was not completed. Finally, 242 patients were
included, 142 (58.7%) women and 100 (41.3%) men with
a mean age of 48.9 ± 16.6 and 49 ± 16.5 years, respect-
ively. Women were less likely to have previous/current
tobacco (28.9% vs 62%) or alcohol (4.2% vs 24%) use and
diabetes (5.6% vs 14%) than men.
At diagnosis, no gender differences were found by the
Curaçao Criteria. The genetic study was positive for
ENG mutations in 80 (49 women) patients, for ACVRL1
in 75 (42 women) and negative in 17 (11 women) pa-
tients (all of them with a “definite” diagnosis according
to Curaçao Criteria). There were no statistically signifi-
cant differences regarding the presence of anemia, iron
defficiency or liver function alterations (Table 1).
HHT involvement
Predefined hepatic manifestations were more frequent in
women than men (7.1% vs 0%). Women showed more
often ischemic cholangitis or right-upper abdominal pain
with bile duct dilation (4.2% vs 0%) and high-output car-
diac failure caused by liver involvement (5.6% vs 0%),
with resulting higher mean cardiac index (3.21 ± 0.87 vs
2.87 ± 0.75, L/min/m2). Hepatic involvement at CT was
also more frequently found in women (59.8% vs 47%),
mainly for arteriovenous shunt (28.2% vs 13%) and bile
duct dilatation (4.9% vs 0%). There were no statistically
significant differences in non-hepatic intra-abdominal
HHT-related vascular involvement between genders.
R-L shunting grades ≥2 at contrast TTE were more
frequently found in women compared to men (37.3% vs.
24%). This finding was consistent with a higher preva-
lence of pulmonary AVMs (35.2% vs 23%) at thoracic
CT in women. Central nervous system manifestations or
vascular imaging did not show significant differences
beetwen genders. Overall, no differences were found in
GI involvement between women and men (20.4% vs
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23%). However, duodenal telangiectasia were more fre-
quent in men than women (21% vs 9.8%) (Table 2).
HHT severity during follow-up
Mean follow-up in women and men was 41.9 ± 25.8 and
40.4 ± 25.3 months, respectively. There were no signifi-
cant differences between women and men in the base-
line ESS (3.47 ± 2.19 vs 3.65 ± 2.12), mean ESS assessed
at each visit during follow-up (2.21 ± 1.76 vs 2.52 ± 1.71)
or in the number of patients with moderate (42.9% vs
37%) or severe ESS (6.3% vs 8%).
The Simple Clinical Scoring Index was higher in women
(3.38 ± 1.20 vs 2.03 ± 1.24). More men were considered at
low risk of harboring clinically significant liver disease
than women (25.3% vs 61%), while all patients at high risk
were women (4.9% vs 0%).
The HHT-score was similar in both groups (2.31 ±
1.06 vs 2.09 ± 0.88). No patients showed diffuse pulmon-
ary AVMs, according to the HHT-score definition [25].
We have found no statistically significant differences be-
tween women and men regarding moderate (33.1% vs
29%) or severe (4.9% vs 1%) categories.
Women needed invasive treatments more often than
men (28.2% vs 16%). Men needed attention to the ED
more often than women (48% vs 28.2%), without statisti-
cally significant differences in severe anemia (hemoglobin







Age, years (mean ± SD) 48.9 ± 16.6 49 ± 16.5 0.995
Smoke (active or history) 41 (28.9%) 62 (62%) < 0.001
Alcohol (active or history) 6 (4.2%) 24 (24%) < 0.001
Hypertension 34 (23.9%) 25 (25%) 0.851
Diabetes Mellitus 8 (5.6%) 14 (14%) 0.026
Dyslipidemia 38 (26.8%) 29 (29%) 0.701
Heart failure* 5 (3.5%) 2 (2%) 0.703
Lung disease 20 (14.1%) 14 (14%) 0.985
Cancer 11 (7.7%) 11 (11%) 0.416
Venous thromboembolic disease 2 (1.4%) 4 (4%) 0.240
Atrial fibrillation 15 (10.6%) 4 (4%) 0.056
Curaçao criteria,
Epistaxis 134 (94.4%) 99 (99%) 0.085
Telangiectasia 135 (95.1%) 99 (99%) 0.145
Visceral involvement 119 (83.8%) 73 (73%) 0.056
Family history 137 (96.5%) 91 (91%) 0.072
Curaçao criteria ≥3 135 (95.1%) 97 (97%) 0.315
Genetic test, 102 (71.8%) 70 (70%) 0.757
ENG 49 (34.5%) 31 (31%) 0.670
ACVRL1 42 (29.6%) 33 (33%) 0.407
Negative 11 (7.7%) 6 (6%) 0.515
Blood test,
Hemoglobin levels, g/dL (mean ± SD) 12.5 ± 2.2 13.4 ± 2.9 0.007
Anemia** 45 (31.7%) 39 (39%) 0.247
Iron deficiency*** 85 (59.8%) 59 (59%) 0.937
AST, μkat/L (mean ± SD) 0.35 ± 0.19 0.35 ± 0.12 0.874
AF, μkat/L (mean ± SD) 1.36 ± 0.84 1.97 ± 7.82 0.455
Bilirubin, μmol/L (mean ± SD) 8.67 ± 5.74 10.01 ± 7.10 0.133
Abbreviations: ACVRL1 activin A receptor type II-like 1, ENG Endoglin, AST aspartate aminotransferase, AF alkaline phosphatase
* Heart failure due to cardiovascular heart disease
** Anemia was defined as hemoglobin levels < 12 g/dL in women and < 13 g/dL in men
*** Iron deficiency was defined as blood ferritin levels < 15 μg/L.
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Hepatic manifestations 10 (7.1%) 0 0.006
Ischemic cholangitis/right-upper abdominal pain 6 (4.2%) 0 0.044
Heart failure* 8 (5.6%) 0 0.022
Hepatic encephalopathy 0 0 –
TTE 139 (97.9%) 97 (97%) 0.693
Cardiac index, L/min/m2 (mean ± SD) 3.21 ± 0.87 2.87 ± 0.75 0.010
Cardiac Index > 4 17 (11.9%) 4 (4%) 0.055
Abdominal CT 126 (88.7%) 90 (90%) 0.754
Hepatic involvement 85 (59.8%) 47 (47%) 0.024
Arteriovenous shunt 40 (28.2%) 13 (13%) 0.026
Bile duct dilatation 7 (4.9%) 0 0.043
Portovenous shunt 13 (9.1%) 9 (9%) 0.590
Arterioportal shunt 28 (19.7%) 19 (19%) 0.417
Hepatic telangiectasia 58 (40.8%) 27 (27%) 0.182
FNH/NRH 10 (7%) 5 (5%) 0.827
Tortuous or enlarged hepatic artery 30 (21.1%) 13 (13%) 0.346
Other intrabdominal involvement at abdominal CT 46 (32.4%) 36 (36%) 0.639
Pancreatic 27 (19%) 19 (19%) 0.514
Splenic 13 (9.1%) 10 (10%) 0.912
Renal 6 (4.2%) 6 (6%) 0.675
Arterial 1 (0.7%) 2 (2%) 0.582
Pulmonary assessment
Pulmonary Manifestations 14 (9.9%) 9 (9%) 0.822
Dyspnea 7 (4.9%) 2 (2%) 0.313
Respiratory failure 5 (3.5%) 1 (1%) 0.405
Hemoptysis 0 2 (2%) 0.170
Ischemic stroke 6 (4.2%) 5 (5%) 0.765
Abscess 4 (2.8%) 2 (2%) 1.000
TTE 139 (97.9%) 97 (97%) 0.693
R/L shunt contrast TTE 99 (69.7%) 62 (62%) 0.128
Shunt ≥2 53 (37.3%) 24 (24%) 0.022
sPAP at TTE, mmHg (mean ± SD) 32.92 ± 10.21 31.28 ± 10.07 0.387
sPAP> 40mmHg 15 (10.5%) 5 (5%) 0.164
Thoracic CT 57 (40.1%) 24 (24%) 0.007
Pulmonary AVMs 50 (35.2%) 23 (23%) 0.036
CNS assessment
CNS manifestations 3 (2.1%) 1 (1%) 0.644
Cerebral haemorrhage 1 (0.7%) 1 (1%) 1.000
Headache 2 (1.4%) 0 0.513
CNS imaging study 49 (34.5%) 42 (42%) 0.257
Pathological vascular imaging 7 (4.9%) 5 (5%) 0.706
Gastrointestinal assessment
Suspected and studied 34 (23.9%) 24 (24%) 0.992
GI telangiectasia 29 (20.4%) 23 (23%) 0.223
Location of telangiectasia:
Stomach 25 (17.6%) 17 (17%) 0.903
Duodenum 14 (9.8%) 21 (21%) 0.015
Colon 4 (2.8%) 6 (6%) 0.326
Ileum-Jejunum** 10 (7.1%) 7 (7%) 0.129
Abbreviations: AVM arteriovenous malformation, CT computed tomography, sPAP systolic pulmonary artery pressure, FNH/NRH focal nodular
hyperplasia/nodular regenerative hyperplasia, TTE Transthoracic echocardiography, R/L Right-left, CNS central nervous system,
GI gastrointestinal;
* Heart failure due to liver involvement
** Video capsule endoscopy was performed in 12 women and 11 men
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level < 8 g/dL or RBC transfusion requirements), hospital
admissions or mortality, or when considering any of these
adverse outcomes (Table 3).
HHT severity according to HHT1 or HHT2 subtypes
HHT1 and HHT2 were documented in 155 (64%) out of
the 242 patients included. Among them, 80 patients had
HHT1 (49 women and 31 men) and 75, HHT2 (42
women and 33 men). There were no gender differences
in epistaxis according to ESS in both HHT1 and HHT2.
However, women showed higher mean of Simple Clin-
ical Scoring Index when compared to men, either among
HHT1 (2.97 ± 1.08 vs 1.62 ± 1.04) and HHT2 (3.64 ± 1.25
vs 1.93 ± 1.23) patients. Similarly, less women showed
low risk of harboring clinically significant liver disease
compared to men in both HHT1 (40.8% vs 67.8%) and
HHT2 (14.3% vs 63.6%). Among HHT2 patients, women
needed invasive treatment more often than men (16.7%
vs 0%) but not in HHT1. There were no statistically sig-
nificant differences in the HHT-score or adverse out-
comes between women and men nor in HHT1 nor in
HHT2 patients (Table 4).
Discussion
To our knowledge, this is the first study after massive
screening due to publication of international guidelines,
assessing gender differences on clinical severity in HHT
patients, either as a whole group or separetely by HHT1
and HHT2 [10]. In our series, hepatic manifestations
were detected in 7.1% of women, while no man showed
any of these manifestations. Women specifically showed
heart failure signs and symptoms caused by liver in-
volvement and hepatic arteriovenous shunt and biliar in-
volvement more often than men [19, 28]. In fact, the
Simple Clinical Scoring Index included female gender as
a risk factor for developing clinically significant hepatic






Follow-up, months (mean ± SD) 41.9 ± 25.8 40.4 ± 25.3 0.647
ESS
ESS at baseline (mean ± SD) 3.47 ± 2.19 3.65 ± 2.12 0.536
ESS during follow-up (mean ± SD) 2.21 ± 1.76 2.52 ± 1.71 0.242
ESS≥ 4 61 (42.9%) 37 (37%) 0.379
ESS≥ 7 9 (6.3%) 8 (8%) 0.604
Simple Clinical Scoring Index 3.38 ± 1.20 2.03 ± 1.24 < 0.001
Low 36 (25.3%) 61 (61%) < 0.001
Intermediate 90 (63.4%) 31 (31%) < 0.001
High 7 (4.9%) 0 0.043
HHT-score 2.31 ± 1.06 2.09 ± 0.88 0.083
Mild 88 (62%) 69 (69%) 0.259
Moderate 47 (33.1%) 29 (29%) 0.532
Severe 7 (4.9%) 1 (1%) 0.245
Invasive treatment
Pulmonary embolization 34 (23.9%) 16 (16%) 0.126
Brain embolization 2 (1.4%) 0 0.470
Liver transplantation 2 (1.4%) 0 0.513
Young surgery 3 (2.1%) 0 0.270
Anyone of the above 40 (28.2%) 16 (16%) 0.027
Adverse outcomes
Hemoglobin < 8 g/dL or RBC transfusion 49 (34.5%) 33 (33%) 0.578
RBC transfusion 37 (26.1%) 27 (27%) 0.870
ED visit 40 (28.2%) 48 (48%) 0.002
Hospital admission 27 (19%) 26 (26%) 0.196
Mortality 4 (2.8%) 4 (4%) 0.721
Anyone of the above 70 (49.3%) 53 (53%) 0.570
Abbreviations: EES Epistaxis Severity Score, RBC red blood cell, ED emergency department
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involvement [19]. This female predominance in preva-
lence and severity of liver involvement is in agreement
with the four published series of HHT patients with liver
transplantation, where between 83.3 and 92.8% of the
patients were women [24, 32–34]. Moreover, 14 (60.8%)
out of 23 of patients with high-output heart failure and
all cases (n = 12) of isolated symptomatic biliar disease
from the European Liver Transplant Registry were fe-
males, similar to our observation [24]. In fact, decom-
pensated high output cardiac failure and biliary
complications are the most frequent causes of liver
transplantation [24, 32–34]. Similar to previous studies,
among patients with genotype data available from our
cohort, those at high risk of harboring clinically signifi-
cant liver disease had ACVRL1 mutation [6, 19]. A better
understanding of liver involvement in HHT and im-
provements in selective screening and close monitoring
from a hepatic standpoint, might contribute to early de-
tection of those patients who will develop symptomatic
liver disease and probably need liver transplantation, as
female HHT2 population.
Although women also showed more prevalence of pul-
monary AVMs, differently from hepatic involvement,
they presented similar clinical pulmonary manifestations
to men. Interestingly, some previous studies showed
similar prevalence of pulmonary AVMs in women, al-
though others showed that men are at greater risk of
HHT related brain abscesses [16, 35–37]. In contrast to
previous studies showing a higher prevalence of brain
AVMs in women, we have found no gender differences
[38–41]. However both in our study and the one by Let-
teboer et al., screening of brain AVMs was only per-
formed according to either patient’s symptoms or family
history, so the number of asymptomatic brain AVMs
might be underestimated [42].
Regarding nasal or GI telangiectasia, neither ESS nor
GI involvement (confirmed by endoscopic digestive
study) did not show significant gender differences in our
series. Surprisingly, our data revealed that men showed
more telangiectasia in the duodenum. This finding
should be confirmed in further studies. Our study also
showed that women needed more invasive treatments
Table 4 Gender differences in HHT severity according to HHT1 or HHT2 subtypes
HHT 1 (n = 80) P value HHT2 (n = 75) P value
Female (n = 49) Male (n = 31) Female (n = 42) Male (n = 33)
ESS 2.82 ± 1.95 2.81 ± 1.95 0.977 3.67 ± 1.96 3.81 ± 1.80 0.744
ESS Control 2.12 ± 1.59 2.15 ± 1.89 0.937 2.25 ± 1.65 2.76 ± 1.50 0.238
ESS≥ 4 16 (32.7%) 7 (22.6%) 0.332 20 (47.6%) 14 (42.4%) 0.669
ESS≥ 7 1 (2%) 1 (3.2%) 1.000 2 (4.8%) 1 (3.1%) 1.000
Simple Clinical Scoring Index 2.97 ± 1.08 1.62 ± 1.04 < 0.001 3.64 ± 1.25 1.93 ± 1.23 < 0.001
Low 20 (40.8%) 21 (67.8%) 0.002 6 (14.3%) 21 (63.6%) < 0.001
Intermediate 29 (59.2%) 6 (19.4%) 0.002 26 (61.9%) 10 (30.3%) 0.003
High 0 0 5 (11.9%) 0 0.058
HHT-score 2.24 ± 0.99 2.13 ± 0.86 0.599 2.35 ± 1.05 1.93 ± 0.82 0.058
Mild 30 (61.2%) 21 (67.7%) 0.429 28 (66.7%) 25 (75.8%) 0.391
Moderate 19 (38.8%) 9 (29%) 0.429 11 (26.2%) 8 (24.2%) 0.847
Severe 0 0 3 (7.1%) 0 0.251
Invasive treatment,
Pulmonary embolization 17 (34.7%) 12 (38.7%) 0.716 5 (11.9%) 0 0.063
Brain embolization 1 (2%) 0 1.000 1 (2.4%) 0 1.000
Liver transplantation 0 0 1 (2.4%) 0 1.000
Young surgery 0 0 1 (2.4%) 0 1.000
Anyone of the above 18 (36.7%) 12 (38.7%) 0.859 7 (16.7%) 0 0.016
Adverse outcomes,
Hemoglobin < 8 g/dL or RBC transfusion 8 (16.3%) 5 (16.1%) 1.000 16 (38.1%) 11 (33.3%) 0.452
ED visit 8 (16.3%) 11 (35.5%) 0.050 12 (28.6%) 16 (48.5%) 0.077
Hospital admission 6 (12.2%) 8 (25.8%) 0.120 8 (19%) 3 (9.1%) 0.328
Mortality 0 0 2 (4.8%) 1 (3%) 1.000
Anyone of the above 17 (34.7%) 13 (41.9%) 0.515 22 (52.4%) 16 (48.5%) 0.738
Abbreviations: EES Epistaxis Severity Score, RBC red blood cell, ED emergency department
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during follow-up and that men visited the ED more
often. However there were no gender differences regard-
ing mortality or other adverse outcomes.
Though no differences between genders in terms of
mortality were found, the reason for higher severity in
liver involvement among women is still unknown and
deserves special attention. The higher prevalence of
women in our study, as it was in previous studies, does
not justify this finding [12, 21, 22]. When assessing gen-
der differences among patients with HHT1 or HHT2
separately, women had more severe liver involvement
both in HHT1 and HHT2 patients. A higher impact in
the angiogenesis process mediated by mutations in the
signalling BMP9-Endoglin-ALK1-Smad hub among
women, could be an explanation. However, this hypoth-
esis does not justify the specific severity of liver involve-
ment in women. The benefit of estrogenic therapy in
HHT might suggest that a hormonal component could
influence angiogenesis. Different studies have performed
immunohistochemistry analyses of oestrogen and pro-
gesterone receptors expression among HHT patients
with other vascular malformations [43–45]. These stud-
ies resulted in controversial results, and do not support
a critical role of hormonal receptors in mucosa telangi-
ectasia from HHT patients. Therefore, other unknown
mechanisms should be involved in gender differences.
New insights in the underlying mechanisms may help to
gain a better understanding of HHT pathophisiology
and angiogenesis process, and could help to develop new
treatments or drug repositioning [46–49].
Our study has several strenghts and limitations that
should be mentioned. A relatively low number of pa-
tients with severe clinical manifestations of hepatic and
pulmonary involvement were included. Reasons for that
might be that our HHT multidisciplinary referral unit at-
tends all HHT patients and not only those more severely
ill patients referred for invasive treatments. Moreover,
our study was performed in a large real-world cohort of
HHT patients with a consistent diagnosis by a special-
ized multidisciplinary team. Interestingly, all data were
prospectively collected during long-term follow-up after
HHT diagnosis, enhancing the ability to reflect the nat-
ural history of the disease and the wide spectrum of
HHT vascular involvement. Finally, it should be noted
that neither the Simple Clinical Scoring Index nor the
general HHT score have been externaly validated [19,
25].
Conclusions
In conclusion, the assessment of gender differences in
overall HHT patients or separately by HHT1 and HHT2,
revealed that women showed more severe liver involve-
ment than men. Moreover, women had a higher preva-
lence of pulmonary AVMs and a higher need for
invasive procedures, while men required ED assessment
more frequently. No other gender differences were
found in severity by using different reported scores, nor
in mortality. These data might help physicians to better
individualize follow-up according to gender and
optimize therapeutic interventions in HHT patients.
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